Written by ι Stock Market Media Group Staff — December 18, 2013
The executives at Nuvilex, Inc. (OTCQB: NVLX) and its subsidiary, Medical Marijuana Sciences, Inc., had to take note of recent results released in a marijuana study done by a group of researchers in Spain. The study used a type of encapsulation to inhibit brain cancer cell growth in mice. These researchers seem to be speaking Nuvilex’s language with the biotech’s recent acquisitions of exclusive worldwide rights to a cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™ for the development of treatments for diabetes and for any and all types of cancer.
In the study, the researchers found that the local administration of microparticles loaded with the two major ingredients of marijuana, tetrahydrocannabinol (THC) and cannabidiol (CBD), reduced tumor growth in a mouse model of human glioma (brain cancer). According to the data, the anti-cancerous molecules THC and CBD used in the study were encapsulated forming microparticles that acted as the drug delivery system to the cancer in the mice.
The small spheres serve as a microparticle targeted treatment system as does the Cell-in-a-Box technology being used by Nuvilex that has undergone both human clinical trials and animal studies in an effort to develop treatments for advanced, inoperable pancreatic cancer, breast cancer, and diabetes. The researchers in the Spanish study noted that a microparticle delivery system offers the benefits of controlling drug release, improving therapeutic effects, prolonging biological activity, and decreasing administration frequency.
The study showed that when microencapsulated THC and CBD were directly administered to human glioma cancer cells grafted to mice, they decreased cell proliferation, decreased angiogenesis (the penetration of blood vessels into tumors which promote metastasis), and enhanced apoptosis (the programmed death of cells). Nuvilex has stated that its subsidiary will attempt to use the Cell-in-a-Box encapsulation technology in its medical marijuana research to develop treatments for some of the most hard-to-treat cancers.
The data out of Spain certainly suggests there is a real opportunity to make advancements with microencapsulation, and with Nuvilex holding the exclusive rights to an encapsulation technology that has certainly proved itself, there could be a promising future for Medical Marijuana Sciences to optimize the use of cannabinoids as anticancer agents.
Commenting on the study, Dr. Gerry Crabtree, COO of both Nuvilex and Medical Marijuana Sciences stated, “We are well aware of the studies done in Spain with microparticles containing THC and CBD and their effects on gliomas in mice. While the encapsulation technology used by those researchers differs from that used by us, both technologies can rightly be called targeted treatments. Most importantly, the work done by those in Spain adds to the mounting scientific evidence that cannabinoids such as THC and CBD are indeed effective anticancer agents, and most significantly, that these substances from marijuana work against one of the deadliest forms of brain cancer, and of cancer as a whole.”